Panic Disorder Market: Trend, Size and Forecast (2025-2034)

Market Overview

The panic disorder market is an essential part of the global mental health landscape, primarily focused on the treatment and management of panic disorders and related conditions such as generalized anxiety disorder (GAD), social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD). The market has seen an increasing emphasis on mental health improvement, with growing awareness and initiatives surrounding anxiety and panic disorders. As mental health issues become more recognized worldwide, the demand for effective treatments such as therapies, medications, and interventions is expected to rise. This has led to the market’s steady growth, which is projected to continue expanding in the forecast period.

Market Size and Share

The panic disorder market in the 7 major markets was valued at USD 9.7 billion in 2024. This market is anticipated to grow at a compound annual growth rate (CAGR) of 4.18% during the forecast period of 2025-2034, reaching a projected value of USD 14 billion by 2034. The increase in market size is attributed to the rising awareness surrounding mental health, advancements in pharmaceutical treatments, and an overall push to reduce the stigma around mental health disorders. The continued growth is likely to be fueled by demand for both therapy and drug-based treatments.

Market Trends

• Rising Focus on Mental Health Awareness
  The growing recognition of the importance of mental health and its impact on overall well-being has driven the panic disorder market. Campaigns and initiatives led by governments and non-government organizations (NGOs) have contributed to the destigmatization of panic and anxiety disorders, encouraging individuals to seek treatment. This increase in awareness has resulted in greater demand for both therapeutic interventions and pharmaceutical products tailored to anxiety disorders.
• Increase in Pharmaceutical Developments
  There has been significant progress in developing new and improved medications for the treatment of panic disorders. With the introduction of novel drug classes, such as serotonin-norepinephrine reuptake inhibitors (SNRIs), and advancements in existing drugs like benzodiazepines and selective serotonin reuptake inhibitors (SSRIs), patients now have access to more effective and safer treatment options. This is fueling the market growth as new medications provide better symptom control and fewer side effects.
• Adoption of Cognitive Behavioral Therapy (CBT)
  Cognitive-behavioral therapy (CBT) is one of the most common and effective forms of psychotherapy used to treat panic disorders. CBT focuses on changing negative thought patterns and behaviors that contribute to anxiety. The growing adoption of CBT, both in-person and online, is positively influencing the market as an increasing number of individuals seek non-drug-based treatment options to manage panic disorder symptoms. The flexibility and effectiveness of CBT contribute to its increasing popularity.
• Telemedicine and Digital Therapies
  With the rise of telehealth services and digital therapeutic tools, more patients are accessing panic disorder treatments from the comfort of their homes. Virtual CBT sessions and mobile applications designed to manage anxiety and panic disorders are increasingly being used in the treatment process. These innovations provide greater accessibility, especially in regions where mental health services are limited or underfunded, helping to drive market growth.

Get a free sample request: https://www.expertmarketresearch.com/reports/panic-disorder-market/requestsample

Market Analysis

• Breakdown by Type
  Panic disorder is often associated with other mental health conditions, such as agoraphobia, social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), bipolar disorder, and PTSD. Among these, generalized anxiety disorder (GAD) and agoraphobia are significant contributors to the panic disorder market due to their high prevalence. These types often co-occur with panic attacks and require targeted therapies and medications, expanding the market's scope.
• Therapy Segmentation
  Therapy plays a vital role in treating panic disorders, with cognitive-behavioral therapy (CBT) and electroconvulsive therapy (ECT) being the most common treatments. CBT is considered a first-line treatment for panic disorders due to its efficacy in addressing the root causes of anxiety. On the other hand, ECT is used for patients with severe cases where other treatments have not been effective, contributing to its market share within the therapeutic segment.
• Drug Class Segmentation
  The panic disorder drug market consists of various classes, including benzodiazepines (BZD), antidepressants (SSRIs, SNRIs), monoamine oxidase inhibitors (MAOIs), and others such as pregabalin and buspirone. Benzodiazepines are often prescribed for short-term use due to their rapid onset of action in treating panic attacks, while SSRIs and SNRIs are commonly used for long-term management. The diversity in drug classes allows healthcare providers to tailor treatments based on patient needs.
• Route of Administration
  The most common routes of administration for panic disorder treatments are oral and parenteral (injectable). Oral medications are typically preferred due to ease of use, with patients taking prescribed doses in pill or capsule form. Parenteral administration is more often used in emergency situations or for patients who cannot tolerate oral medications, contributing to the drug delivery segment’s diversity.

Scope of the Report

The report provides a comprehensive analysis of the panic disorder market, including market size, trends, key drivers, and constraints. It also examines the market from different angles, including product types, therapy options, drug classifications, and routes of administration. Additionally, the report provides a breakdown of the market by region, offering insights into geographical differences in demand and growth potential. The report also forecasts future trends and opportunities based on the analysis of historical data.

Market Growth

The growth of the panic disorder market is largely driven by an increased focus on mental health care, coupled with advances in the development of more effective medications and therapies. The rising incidence of panic disorder and other anxiety-related conditions, especially in developed countries, has prompted healthcare systems to provide more targeted treatments. Furthermore, the growing acceptance of telemedicine and digital therapies, along with better diagnostic tools, is expected to contribute to market expansion.

The market also benefits from a shift towards personalized treatment plans. Advances in genetic testing and precision medicine allow clinicians to better match treatments to individual patients, improving outcomes and reducing side effects. As such, opportunities for growth will emerge from innovations in treatment personalization and the expansion of digital mental health solutions.

Recent Developments & Challenges

• Innovation in Medication and Therapy
  Recent developments in drug formulations, such as extended-release versions of antidepressants and the introduction of novel anti-anxiety drugs like pregabalin, are reshaping the market. Additionally, therapy advancements such as online CBT platforms are expanding access and convenience for patients.
• Regulatory Approval Delays
  One of the key challenges facing the market is the lengthy approval process for new drugs and therapies. Regulatory hurdles can delay the introduction of innovative treatments, impacting the overall market growth rate. Drug safety concerns also pose challenges to the adoption of new treatments, necessitating thorough clinical trials and studies before approval.
• Increasing Demand for Non-Pharmacological Treatments
  As patients and healthcare providers increasingly prefer non-drug-based therapies due to concerns about medication side effects, the market faces competition from alternative treatments such as mindfulness-based cognitive therapy and relaxation techniques. This shift is shaping the future landscape of panic disorder management.
• Cost of Therapy and Medication
  The cost of advanced treatments, both pharmacological and therapeutic, remains a significant barrier to market growth. In countries with limited mental health resources, the cost of long-term therapy may deter patients from seeking treatment, impacting the market's reach in these regions.

Key Players

• Teva Pharmaceutical Industries Ltd
  Teva Pharmaceutical Industries is a leading player in the panic disorder market, offering generic and branded medications for the treatment of anxiety and panic disorders. Known for its comprehensive portfolio of products, Teva’s offerings, such as anti-anxiety medications and antidepressants, play a critical role in the market. The company focuses on expanding access to affordable medications and is actively involved in research to develop innovative treatments.
• Sun Pharmaceutical Industries Ltd
  Sun Pharmaceutical Industries is a key player in the global pharmaceutical market, offering a range of medications used to treat mental health conditions, including panic disorder. With a strong focus on research and development, the company is committed to producing high-quality, cost-effective treatments that improve patient outcomes and accessibility in mental health care.
• AstraZeneca
  AstraZeneca is a major pharmaceutical company that develops treatments for a wide range of mental health conditions, including panic disorder. With a strong focus on neuroscience, AstraZeneca’s products, such as antidepressants and antianxiety medications, are widely used in the treatment of panic disorders. The company continues to explore new drug formulations and therapies to meet the needs of patients worldwide.
• Mylan
  Mylan is known for its generic and branded drug offerings in the field of mental health treatment. Its portfolio includes medications used to treat panic disorder, such as benzodiazepines and antidepressants. Mylan is focused on providing affordable treatment options for patients across the globe, contributing to its strong presence in the market.

Other key players in the panic disorder market include F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Boehringer Ingelheim, Eli Lilly and Company, and Neurocrine Biosciences, Inc.

FAQs

• What is panic disorder?
  Panic disorder is a mental health condition characterized by recurrent and unexpected panic attacks, often accompanied by physical symptoms such as a rapid heartbeat, sweating, and difficulty breathing.
• What are the common treatments for panic disorder?
  Common treatments include medications (such as benzodiazepines and antidepressants) and cognitive-behavioral therapy (CBT), which helps individuals manage anxiety through behavioral changes and thought reframing.
• How is the panic disorder market growing?
  The panic disorder market is growing due to increasing mental health awareness, the development of new treatments, and the rise of telemedicine. The market is expected to grow at a CAGR of 4.18% during the forecast period.
• Which companies are leading the panic disorder market?
  Key players in the market include Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, AstraZeneca, and Mylan, who contribute significantly to the development and distribution of panic disorder treatments.

More Related Report: https://www.expertmarketresearch.com/healthcare-articles/top-viral-inactivation-companies